Loading…

YD Bio LimitedYDESCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties
Momentum weak 23
Mkt cap
$423M
US dollars, full cap
Free float
20%
of shares outstanding
$/day
$1.80M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 6.4%
Hurdle
n/a
no reverse DCF
Close · USD$3.23
1Dn/a
1W-12.7%
1M-30.7%
3M+22.8%
6M-58.2%
YTD-73.5%
1Y-82.8%
ATR %19.7%
Beta0.19
52w lowhigh85.3% off high

What YD Bio does

Employees: 15

YD Bio at a glance

Size YD Bio (YDES) is a United States Health Care company (Medical Specialties) with a market value of $423M, the 2814th largest of 3,117 United States companies the cockpit tracks. Shares closed at $3.23 on 6 Nov 2026.

Performance Over six months the shares fell 58.2%, against -16.0% for the median peer and -1.1% for the United States market (cap-weighted) — 2nd lowest of 20 in its peer set.

Growth Revenue grew 16.9% over the last twelve months (peer median +8.4%); the operating margin is -883.3% (peer median 5.2%).

Valuation It trades at 704.2× enterprise value to sales against a peer median of 4.5× (most expensive of 21).

Short interest Short interest is 0.3% of the free float (15 Oct 2026).

Relative performance

25507510011 May 202611 Aug 20266 Nov 2026Peer median 84YDES 42
Six months, rebased to 100: YD Bio against the median of its 20 peers (local-currency closes).

YD Bio financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenuen/a$596,817$510,360$0$0
Revenue growth—+17%———
Gross profitn/a-$42,150$50,621$0$0
EBITDAn/a-$5.06M-$1.36M-$2.07M-$2.32M
Net incomen/a-$8.31M-$1.41M-$2.55M$3.79M
Free cash flown/a-$8.04M-$1.30M-$2.02M-$3.02M
Capital expendituren/a$1.44M$2.91M$0$0
Total debtn/a$6,764$22,265$0$0

Quarterly statements and history in the cockpit →

YD Bio competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-25%0%+25%SSIISI605186NPCE688133MASS458870688338CERS301097BWAY4685304736YDES6-month return →1-month return →
Up and to the right = strong over both horizons. YD Bio is the large dot.

Fundamentals: revenue growth against valuation

0%+25%+50%+75%0×200×400×600×SSIISI605186NPCE688133MASS458870301097BWAY468530YDESRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. YD Bio is the large dot.

YD Bio competitors and peer comparison

How YD Bio compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

YD Bio against its 20 peers (data as of 6 Nov 2026)
MeasureYDESPeer medianRank in peer set
1-month return-30.7%-8.6%2nd lowest of 21
6-month return-58.2%-16.0%2nd lowest of 20
Distance from 52-week high-85.3%-37.7%lowest of 21
Revenue growth (TTM)+16.9%+8.4%7th highest of 21
Operating margin-883.3%5.2%2nd lowest of 21
EV / Sales704.2×4.5×most expensive of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
YD Bio YDESUnited States$423M-58%+17%-883%704.2×n/an/a
SS Innovations International SSIIUnited States$423M-45%+90%-16%8.0×n/an/a
Shoulder Innovations SIUnited States$428M+56%+61%-59%5.7×n/an/a
Shanghai General Healthy Information & Technology 605186.SSChina$417M+3%+12%6%8.1×55.5%+3.8%
NeuroPace NPCEUnited States$429M-32%+12%-15%4.5×n/an/a
Shanghai Titan Scientific 688133.SSChina$432M-22%-5%-5%1.5×n/an/a
Medcaptain Medical Technology 2041.HKHong Kong$412Mn/a+19%3%1.6×23.3%+18.1%
908 Devices MASSUnited States$436M+29%+1%-35%5.5×n/an/a
SEERS 458870.KSSouth Korea$409M-70%+425%43%5.5×-9.1%+247.0%
Beijing Succeeder Technology 688338.SSChina$408M-15%-4%31%5.4×9.8%+3.4%
Cerus CERSUnited States$408M-23%+14%-12%1.9×n/an/a
Shanghai Kehua Bio-Engineering 002022.SZChina$407M-14%+3%-45%1.9×n/an/a
Ningbo Tianyi Medical Appliance 301097.SZChina$407M-20%+46%8%4.3×n/an/a
Guangdong Transtek Medical Electronics 300562.SZChina$406M-13%+7%11%2.0×-2.5%-6.0%
Guanhao Biotech 300238.SZChina$440M-25%-7%5%7.8×n/an/a
Chison Medical Technologies 688358.SSChina$443M-16%-1%19%4.4×11.8%+5.6%
Brainsway Ltd Sponsored ADR BWAYUnited States$450M-35%+32%12%6.5×34.3%+18.8%
PROTEINA 468530.KSSouth Korea$450M-2%-59%-1,178%410.3×n/an/a
Taidoc Technology 4736.TWTaiwan$395M0%-6%18%1.9×-8.0%-6.6%
Hunan Sundy Science and Technology 300515.SZChina$453M-13%+10%27%3.7×0.9%+15.6%
Eiken Chemical 4549.TJapan$454M-29%+4%6%1.5×n/an/a

Questions

Which companies are YD Bio's closest peers?
The cockpit's peer set: SS Innovations International (SSII), Shoulder Innovations (SI), Shanghai General Healthy Information & Technology (605186.SS), NeuroPace (NPCE), Shanghai Titan Scientific (688133.SS), Medcaptain Medical Technology (2041.HK), 908 Devices (MASS), SEERS (458870.KS).
Is YD Bio expensive compared with its peers?
On ev / sales it trades at 704.2× against a peer median of 4.5×, most expensive of 21 in its peer set.
How has YD Bio stock performed?
Over six months to 6 Nov 2026 the shares returned -58.2% against -16.0% for the median peer; over one year -82.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.